Since systemic anti-PD-L1 treatment with MV resulted in survival times comparable to MVaPDL1 treatment and systemic anti-CTLA-4 treatment with MV resulted in significantly better survival times compared to MVaCTLA4, it remains to be seen if tumor-targeted delivery of checkpoint inhibitors by MV is superior to MV combination with systemic checkpoint blockade. This evidence concerns the gene CD274 and neoplasm.